Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II sunitinib in extensive-stage or sensitive-relapse small cell lung cancer
NL-OMON33984Phase 2Not yet recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in small cell lung cancer (SCLC), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Disease control rate at 4 weeks. Planned start Feb 2009; status: not yet recruiting.
02
Drugs
sunitinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON33984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33984.